| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7651698 | GALT PHARMS | Prolonged release bioadhesive therapeutic systems |
Sep, 2022
(1 year, 7 months ago) | |
| US6916485 | GALT PHARMS | Prolonged release bioadhesive therapeutic systems |
Sep, 2022
(1 year, 7 months ago) | |
| US8518442 | GALT PHARMS | Prolonged release bioadhesive therapeutic systems |
Sep, 2022
(1 year, 7 months ago) | |
Oravig is owned by Galt Pharms.
Oravig contains Miconazole.
Oravig has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Oravig are:
- US7651698
- US6916485
- US8518442
Oravig was authorised for market use on 16 April, 2010.
Oravig is available in tablet;buccal dosage forms.
Oravig can be used as treatment of oropharyngeal candidiasis.
The generics of Oravig are possible to be released after 11 September, 2022.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Apr 16, 2013 |
Drugs and Companies using MICONAZOLE ingredient
Market Authorisation Date: 16 April, 2010
Treatment: Treatment of oropharyngeal candidiasis
Dosage: TABLET;BUCCAL
More Information on Dosage
ORAVIG family patents
